Dosing & Uses
Dosage Forms & Strengths
cream/lotion/ointment
- 0.1%
Inflammatory Hyperkeratotic Dermatosis
Apply cream, lotion or ointment to affected area qDay
Administration
Do not use with occlusive dressings
Other Indications & Uses
Dermatosis-associated inflammation and pruritus
Potency: Medium
Dosage Forms & Strengths
cream/lotion/ointment
- 0.1%
Inflammatory Hyperkeratotic Dermatosis
<2 years: Safety and efficacy not established
2 years or older: As adults: apply cream, lotion or ointment to affected area qDay
Use beyond 3 weeks not studied
Interactions
Interaction Checker
No Results
Contraindicated
Serious - Use Alternative
Significant - Monitor Closely
Minor
Contraindicated (1)
- mifepristone
mifepristone, mometasone topical. Either increases toxicity of the other by Other (see comment). Contraindicated. Comment: Mifepristone is contraindicated in patients on long-term corticosteriod treatment due to increase risk of adrenal insufficiency.
Serious - Use Alternative (1)
- aldesleukin
mometasone topical decreases effects of aldesleukin by unspecified interaction mechanism. Avoid or Use Alternate Drug.
Monitor Closely (5)
- ceritinib
mometasone topical decreases effects of ceritinib by Other (see comment). Modify Therapy/Monitor Closely. Comment: Closely monitor for severe hyperglycemia (serum glucose >250 mg/dL) and treat appropriately. Patients with history of diabetes or glucose intolerance are at increased risk. .
- corticorelin
mometasone topical decreases effects of corticorelin by pharmacodynamic antagonism. Use Caution/Monitor. Recent or current corticosteroid therapy may blunt the response to corticorelin, potentially interfering with the corticorelin stimulation test results.
- deferasirox
mometasone topical decreases effects of deferasirox by unspecified interaction mechanism. Use Caution/Monitor. Due to the risk for GI bleeding and irritation/ulceration associated with deferasirox, exercise caution when using with corticosteroids, that can also cause gastrointestinal ulceration and/or bleeding.
- hyaluronidase
mometasone topical decreases effects of hyaluronidase by unspecified interaction mechanism. Modify Therapy/Monitor Closely. Patients receiving larger doses of corticosteriods may not experience the desired clinical response to standard doses of hyaluronidase. Larger doses of hyaluronidase may be required.
- omacetaxine
omacetaxine, mometasone topical. Either increases toxicity of the other by Other (see comment). Modify Therapy/Monitor Closely. Comment: Concomitant use with omacetaxine and mometasone topical may enhance the risk of infections and myelosuppression.
Minor (0)
Adverse Effects
Frequency Not Defined
Burning
Itching
Pruritus
Rosacea
Postmarketing Reports
Irritation
Dryness
Folliculitis
Hypertrichosis
Acneiform eruptions
Hypopigmentation
Perioral dermatitis
Allergic contact dermatitis
Secondary infection
Skin atrophy
Striae
Miliaria
Blurred vision
Cataracts
Glaucoma
Increased intraocular pressure
Central serous chorioretinopathy
Warnings
Contraindications
Hypersensitivity
Cautions
Safety/efficacy in children use for longer than 3 wk not established; pediatric patients may be more susceptible to systemic toxicity
Do not use with occlusive dressings
Not for acne, rosacea, perioral dermatitis, diaper dermatitis
If concomitant skin infections are present or develop, use appropriate antifungal or antibacterial agent; if favorable response does not occur promptly, therapy should be discontinued until infection has been adequately controlled
If irritation develops, discontinue therapy and institute appropriate therapy; allergic contact dermatitis with corticosteroids is usually diagnosed by observing failure to heal rather than noting a clinical exacerbation; corroborate observation with appropriate diagnostic patch testing
Use of topical corticosteroids may increase risk of posterior subcapsular cataracts and glaucoma; cataracts and glaucoma reported in postmarketing experience with therapy; avoid contact with eyes; advise patients to report any visual symptoms and consider referral to ophthalmologist for evaluation
Endocrine system effects
- Systemic absorption of topical corticosteroids can produce reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with potential for glucocorticosteroid insufficiency; this may occur during treatment or after withdrawal of treatment
- Manifestations of Cushing's syndrome, hyperglycemia, and glucosuria can be produced in some patients by systemic absorption of topical corticosteroids while on treatment
- Factors that predispose a patient using a topical corticosteroid to HPA axis suppression include use of high potency steroids, large treatment surface areas, prolonged use, use of occlusive dressing, altered skin barrier, liver failure and young age
- Because of potential for systemic absorption, use of topical corticosteroids may require that patients be periodically evaluated for HPA axis suppression; this may be done by using the adrenocorticotropic hormone (ACTH) stimulation test
- If HPA axis suppression documented, attempt to gradually withdraw drug, to reduce frequency of application, or to substitute a less potent corticosteroid; recovery of HPA axis function is generally prompt upon discontinuation of topical corticosteroids; infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur, requiring supplemental systemic corticosteroids
- Pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios
Pregnancy & Lactation
Pregnancy Category: C
Lactation: use caution
Pregnancy Categories
A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.
B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk. C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done. D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk. X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist. NA: Information not available.Pharmacology
Absorption: 0.4%
Metabolism: hepatic P450 enzyme CYP3A4
Excretion: N/A
Potency
Medium
Relative potency: ointment >cream >lotion >solution
Very-high: clobetasol, diflorasone diacetate ointment 0.05%, halobetasol
High: betamethasone dipropionate 0.05%, amcinonide, fluocinonide, desoximetasone, mometasone, diflorasone emollient 0.05%, halcinonide
Medium: triamcinolone, betamethasone valerate 0.1%, fluticasone, flurandrenolide, fluocinolone 0.025%, hydrocortisone
Mild: hydrocortisone 0.5, 1, 2.5% base, desonide, alclometasone
Mechanism of Action
Anti-inflammatory corticosteroid
Images
| BRAND | FORM. | UNIT PRICE | PILL IMAGE |
|---|---|---|---|
| mometasone nasal - | 50 mcg/actuation aerosol |  | |
| mometasone nasal - | 50 mcg/actuation aerosol |  | |
| mometasone nasal - | 50 mcg/actuation aerosol |  | |
| Sinuva sinus - | 1,350 mcg implant |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % cream |  | |
| mometasone topical - | 0.1 % cream |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % cream |  | |
| mometasone topical - | 0.1 % cream |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % solution |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % cream |  | |
| mometasone topical - | 0.1 % cream |  | |
| mometasone topical - | 0.1 % ointment |  | |
| mometasone topical - | 0.1 % solution |  | |
| mometasone topical - | 0.1 % solution |  | |
| mometasone topical - | 0.1 % solution |  | |
| Asmanex Twisthaler inhalation - | 220 mcg/ actuation (14) aerosol |  | |
| Asmanex Twisthaler inhalation - | 220 mcg/ actuation (60) aerosol |  | |
| Asmanex Twisthaler inhalation - | 220 mcg/ actuation (120) aerosol |  | |
| Asmanex Twisthaler inhalation - | 110 mcg/ actuation (30) aerosol |  | |
| Asmanex Twisthaler inhalation - | 220 mcg/ actuation (30) aerosol |  | |
| Asmanex HFA inhalation - | 100 mcg/actuation aerosol |  | |
| Asmanex HFA inhalation - | 200 mcg/actuation aerosol |  | |
| Asmanex HFA inhalation - | 50 mcg/actuation aerosol |  |
Copyright © 2010 First DataBank, Inc.
Formulary
Adding plans allows you to compare formulary status to other drugs in the same class.
To view formulary information first create a list of plans. Your list will be saved and can be edited at any time.
Adding plans allows you to:
- View the formulary and any restrictions for each plan.
- Manage and view all your plans together – even plans in different states.
- Compare formulary status to other drugs in the same class.
- Access your plan list on any device – mobile or desktop.
